Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort?
Mouly, Stéphane; Lloret-Linares, Célia; Sellier, Pierre-Olivier; Sene, Damien; Bergmann, J-F.
; 118: 82-92, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27693910
Predicting clinical relevance of grapefruit-drug interactions: a complicated process.
Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics.
The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall.
Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice.
Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
A validated RP-HPLC method for the evaluation of the influence of grapefruit juice on liver S9 activation of sacubitril.
Influence of grapefruit juice on pharmacokinetics of triptolide in rats grapefruit juice on the effects of triptolide.
In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696).
Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.